TrovaGene (TROV) Shares Gap Up to $0.34

Shares of TrovaGene Inc (NASDAQ:TROV) gapped up before the market opened on Friday . The stock had previously closed at $0.31, but opened at $0.34. TrovaGene shares last traded at $0.36, with a volume of 4006000 shares changing hands.

Several analysts have weighed in on the company. HC Wainwright assumed coverage on TrovaGene in a research note on Thursday, December 21st. They set a “buy” rating and a $1.00 target price on the stock. downgraded TrovaGene from a “buy” rating to a “hold” rating in a research note on Wednesday, November 15th. Finally, Maxim Group downgraded TrovaGene from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $3.70.

The company has a market capitalization of $19.26, a price-to-earnings ratio of -0.39 and a beta of 0.40.

TrovaGene (NASDAQ:TROV) last issued its earnings results on Thursday, November 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.02. The business had revenue of $0.12 million for the quarter. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%. equities research analysts predict that TrovaGene Inc will post -0.78 earnings per share for the current year.

A hedge fund recently raised its stake in TrovaGene stock. Susquehanna International Group LLP increased its stake in TrovaGene Inc (NASDAQ:TROV) by 254.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 488,937 shares of the medical research company’s stock after acquiring an additional 350,906 shares during the quarter. Susquehanna International Group LLP owned approximately 1.28% of TrovaGene worth $357,000 at the end of the most recent quarter. Institutional investors own 13.73% of the company’s stock.

WARNING: This piece was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at

About TrovaGene

Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with's FREE daily email newsletter.

Leave a Reply